Lb Pharmaceuticals (LBRX) Share-based Compensation (2024 - 2026)

Lb Pharmaceuticals' Share-based Compensation history runs 3 years deep, the most recent figure standing at $10000.0 for Q1 2026.

• In Q1 2026, Share-based Compensation fell 98.42% year-over-year to $10000.0; the TTM figure through Mar 2026 stood at $10000.0 (changed N/A YoY), while the FY2025 annual figure was $29.1 million, up 40885.92% from the prior year.
• Share-based Compensation for Q1 2026 stood at $10000.0, down from $4.2 million in the prior quarter.
• The five-year high for Share-based Compensation was $4.2 million in Q4 2025, with the low at $10000.0 in Q1 2026.
• The 3-year median for Share-based Compensation is $118000.0 (2024), against an average of $1.0 million.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation retreated 4.24% in 2025, then slumped 98.42% in 2026.
• Lb Pharmaceuticals' Share-based Compensation stood at $118000.0 in 2024, then jumped by 3451.69% to $4.2 million in 2025, then sank by 99.76% to $10000.0 in 2026.
• Business Quant data shows LBRX's Share-based Compensation at $10000.0 in Q1 2026, $4.2 million in Q4 2025, and $113000.0 in Q3 2025.